SUMMARY
# Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design
## Background and Rationale
Chaperone-mediated autophagy (CMA) is a selective degradation pathway that maintains cellular proteostasis by targeting specific proteins containing KFERQ-like motifs to lysosomes via the LAMP2A receptor and HSC70 chaperone complex. Recent evidence suggests CMA dysfunction may be an upstream pathogenic mechanism in Parkinson's Disease (PD), contributing to alpha-synuclein accumulation and neurodegene
METHODOLOGY NOTES
Phase 1 (Months 1-12): Patient-derived iPSC generation and characterization. Collect skin biopsies from 30 PD patients (early-stage, H&Y 1-2) and 20 age-matched controls. Reprogram to iPSCs using Sendai virus vectors, validate pluripotency markers, and differentiate into midbrain dopaminergic neurons using established protocols with SHH, FGF8, and BDNF. Phase 2 (Months 6-18): CMA pathway analysis in iPSC-derived neurons. Assess LAMP2A protein levels by Western blot and immunofluorescence, measure HSC70 expression, quantify CMA substrate degradation using fluorescent reporters, and analyze alpha-synuclein accumulation by ELISA and proximity ligation assay. Treat with CMA modulators (retinoic acid activation, 6-aminonicotinamide inhibition). Phase 3 (Months 12-24): Clinical biomarker validation. Recruit 100 PD patients and 50 controls for CSF and plasma collection. Measure LAMP2A, HSC70, and CMA substrates by ELISA, quantify alpha-synuclein species by RT-QuIC, assess lysosomal enzymes (c